Loading patent…
AssigneePeking University People;s Hospital
InventorsHeng Cui, Wei Li, Xiaohong Chang, Jie Feng, Hongyan Cheng, Huifang Guo, Yexia Cheng
Estimating the term…
The present invention provides two T-cell epitode peptides of anti-idiotype antibody 6B11 of ovarian cancer, the sequences of which are shown in SEQ ID NO:3 or 6. The present invention also provides the use of such T-cell epitope peptides in the manufacture of vaccines against ovarian cancer and in the treatment and prevention of ovarian cancer. The T-cell epitope peptides of the present invention could specifically kill ovarian cancer cells which are OC166-9 positive, and could find a wide use in the treatment and prevention of ovarian cancer.
An epitope peptide, wherein the amino acid sequence of the epitope peptide:
A pharmaceutical composition for the treatment or prevention of ovarian cancer, comprising both the epitope peptide set forth in SEQ ID NO:3 and the epitope peptide set forth in SEQ ID NO:6.
A method for the treatment or prevention of ovarian cancer, comprising administering the epitope peptide set forth in SEQ ID NO:3 and the epitope peptide set forth in SEQ ID NO:6 simultaneously, sequentially or separately.
(canceled)
(canceled)
Dependencies are inferred from the claim text.